Orexo AB (publ) (0H19.IL)
| Previous close | 16.08 |
| Open | 0.00 |
| Bid | 15.60 x N/A |
| Ask | 17.24 x N/A |
| Day's range | 17.21 - 17.21 |
| 52-week range | 8.70 - 20.78 |
| Volume | |
| Avg. volume | 541 |
| Market cap | 565.107M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.66 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireOrexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
PR NewswireOrexo announces that the condition for early redemption of its existing bonds has been fulfilled
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").
PR NewswireOrexo publishes the Annual and Sustainability Report for 2023
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is attached to this press release.
